The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.

There is a pressing need for a gonorrhea vaccine due to the high disease burden associated with gonococcal infections globally and the rapid evolution of antibiotic resistance in Neisseria gonorrhoeae (Ng). Current gonorrhea vaccine research is in the stages of antigen discovery and the identification of protective immune responses, and no vaccine has been tested in clinical trials in over 30 years. Recently, however, it was reported in a retrospective case-control study that vaccination of humans with a serogroup B Neisseria meningitidis (Nm) outer membrane vesicle (OMV) vaccine (MeNZB) was associated with reduced rates of gonorrhea. Here we directly tested the hypothesis that Nm OMVs induce cross-protection against gonorrhea in a well-characterized female mouse model of Ng genital tract infection. We found that immunization with the licensed Nm OMV-based vaccine 4CMenB (Bexsero) significantly accelerated clearance and reduced the Ng bacterial burden compared to administration of alum or PBS. Serum IgG and vaginal IgA and IgG that cross-reacted with Ng OMVs were induced by 4CMenB vaccination by either the subcutaneous or intraperitoneal routes. Antibodies from vaccinated mice recognized several Ng surface proteins, including PilQ, BamA, MtrE, NHBA (known to be recognized by humans), PorB, and Opa. Immune sera from both mice and humans recognized Ng PilQ and several proteins of similar apparent molecular weight, but MtrE was only recognized by mouse serum. Pooled sera from 4CMenB-immunized mice showed a 4-fold increase in serum bactericidal50 titers against the challenge strain; in contrast, no significant difference in bactericidal activity was detected when sera from 4CMenB-immunized and unimmunized subjects were compared. Our findings directly support epidemiological evidence that Nm OMVs confer cross-species protection against gonorrhea, and implicate several Ng surface antigens as potentially protective targets. Additionally, this study further defines the usefulness of murine infection model as a relevant experimental system for gonorrhea vaccine development.

Introduction

An estimated 87 million new gonorrheal infections occur each year worldwide [1] and rates are rising globally, with a 67% increase in reported infections in the U.S. between 2014 and 2018 [2]. Caused by the Gram-negative bacterium Neisseria gonorrhoeae (Ng), gonorrhea is associated with significant morbidity and mortality that disproportionately affects women and newborns. Lower urogenital tract infections can ascend to cause endometritis and salpingitis in females, and less frequently, epididymitis and orchitis in males. Ng pelvic inflammatory disease can be asymptomatic or acute, and is associated with ectopic pregnancy, infertility and chronic pelvic pain. Disseminated gonococcal infection can occur in either gender [3]. Transmission of gonorrhea to neonates from infected mothers can cause acute neonatal conjunctivitis [4] and there is a clear association between maternal gonorrhea, low-birth weight and pre-mature delivery [5]. The impact of gonorrhea on human health is amplified by its role in increasing both transmission and susceptibility to the human immunodeficiency virus (HIV) [6,7].

Gonorrhea is classified as an urgent public health threat due to decreasing susceptibility to the last remaining reliable monotherapy for gonorrhea, the extended-spectrum cephalosporins. Dual therapy with high-dose ceftriaxone and azithromycin is currently recommended for empirical treatment of gonorrhea in many countries. However, Ng susceptibility to these antibiotics continues to decrease world-wide [8], and alarmingly, treatment failures due to strains that are resistant to these antibiotics have been reported [9,10]. New antibiotics are under development [11,12]; however, the evolutionary success of the gonococcus in outrunning public health efforts to contain it through treatment has reinvigorated the call for a gonorrhea vaccine [13,14].

Early vaccine research was challenged by the discovery that several Ng surface molecules are phase or antigenically variable. There was also no animal model other than chimpanzees for systematic testing of immunogens in challenge studies, and two published clinical trials using a killed whole cell vaccine [15] or purified pili [16] were unsuccessful despite earlier small in-house studies that showed protection from urethral challenge in human male volunteers [17]. Since this time, several conserved and semi-conserved vaccine antigens that elicit bactericidal antibodies or inhibit target function have been identified, some of which show protection in a well-characterized mouse genital tract infection model [13]. How well the mouse model predicts vaccine efficacy in humans is not known, however, due to the strict host-specificity of Ng and a lack of information on correlates of immune protection in humans. There is little immunity to natural infection in humans and mice [18], and there is growing evidence that the adaptive response to Ng infection is suppressed. As recently reviewed by Lovett and Duncan [19], human humoral immune responses to Ng to infection are modest at best and the analysis thereof is complicated by pre-existing antibodies to carbohydrate and protein surface antigens that are induced by commensal Neisseria sp., although antibodies to some antigens are increased by infection. Human cellular responses to Ng infection are less well studied, but appear to be driven by a Th17 pro-inflammatory response. Th1 responses, in contrast, appear suppressed [20], and several pathways that result in reduced antigen presentation and, or inhibition of T cell responses to Ng have been identified using human immune cells and experimentally infected mice [21-25].

Recent epidemiological evidence, however, suggests immunity to gonorrhea can be achieved in humans through vaccination with outer membrane vesicles (OMVs) of the related species, Neisseria meningitidis (Nm). In this cross-sectional study, vaccination of individuals with the serogroup B meningococcal vaccine MeNZB, which consisted of OMVs from an endemic New Zealand strain, was associated with a reduced rate of gonorrhea in adolescents and adults aged 15–30 years old [26]. Using cases of chlamydia as a control, the estimated effectiveness of this meningococcal vaccine against gonorrhea was predicted to be 31%. These data are the first controlled evidence in humans in over 40 years that vaccine-induced protection against gonorrhea is possible. A similar finding was suggested by epidemiological studies on Nm OMV vaccines in Cuba and Norway [27].

To directly test the hypothesis that Nm OMV-based vaccines induce cross-species protection against Ng, here we evaluated the in vivo efficacy of the licensed 4CMenB (“4 Component Meningitis B”; Bexsero) vaccine in a female mouse model of Ng lower genital tract infection. 4CMenB consists of Nm OMVs from the Nm strain used in the MenNZB vaccine and five recombinant Nm proteins [28], only one of which, the neisserial heparin-binding antigen (NHBA), is a feasible vaccine target for gonorrhea [29,30]. Our results show that 4CMenB significantly reduces the Ng bioburden, accelerates clearance of infection, and induces antibodies that recognize Ng outer membrane proteins, several of which are promising vaccine targets. These findings are consistent with epidemiological data that suggest cross-species protection against gonorrhea is possible and validate the gonorrhea mouse model as a useful experimental system for developing vaccines against this human disease.

Results

Optimization of the immunization regimen to induce serum and vaginal antibodies

The recommended dosing regimen for 4CMenB in humans is two 500 μL doses given intramuscularly, four weeks apart. As a preliminary step for mouse immunization/challenge studies, we immunized BALB/c mice with 20, 125, or 250 μL of the 4CMenB vaccine on days 1 and 28 by the subcutaneous (SC) or intraperitoneal (IP) routes to assess safety and immunogenicity. A dose-response in serum IgG1 titers against the 4CMenB vaccine components was detected by ELISA in IP- and SC-immunized mice (S1A Fig), and IgG2a titers were higher in mice given 100 μL or 250 μL compared to 20 μL (S1B Fig). This dose response was mirrored in Western blots using anti-IgG secondary antibody against whole-cell lysates of Nm and six different Ng strains (S1C Fig). Sera from control mice given PBS or Alum adjuvant alone did not recognize any Nm or Ng proteins. No adverse effects were observed following IP injection. Nodules formed at the injection site in SC-immunized mice for all doses given, which resolved over time.

The MenNZB human epidemiology study reported by Petousis-Harris, et al. [26] was based on subjects who received a 3-dose regimen separated by one month. Upon demonstrating that the 250 μL dose of 4CMenB was well-tolerated and induced the highest serum antibody titers, we added a third immunization in subsequent mouse immunization/challenge experiments. Mice were given 250 μL of the formulated vaccine three times by IP or SC injection; controls received Alum or PBS (IP). A 3-week interval between immunizations was used to avoid increasing the age of the mice before challenge, which can reduce susceptibly to Ng. Significantly higher titers of Ng-specific serum total Ig, IgG1, and IgG2a (p < 0.004) but not IgA were detected in SC- and IP-immunized mice against Ng OMVs compared to control groups that received Alum or PBS on day 52 (Fig 1A, 1B, 1C and 1D). Total Ig, IgG1 and IgG2a titers were further elevated by the third immunization in both the IP- and SC-immunized groups (day 31 versus day 52) (p ≤ 0.05). The IgG1/IgG2a ratio was significantly lower for IP-immunized mice on day 31, but similar to SC-immunized mice on day 52 (Fig 1E) due to a marked increase in IgG2a titers in the SC-immunized group after the third immunization (Fig 1C). Vaginal total Ig and IgG1 (p < 0.0001), but not IgG2a or IgA were significantly elevated in vaginal washes collected after the second immunization compared to control groups in IP-immunized mice, but not SC-immunized mice (Fig 1F, 1G, 1H and 1I). Vaginal washes were not collected after the third immunization to avoid altering the vaginal microenvironment before bacterial challenge and cessation of the LeBoot effect, which would increase the number of mice in the undesired stages of the estrous cycle at the time of challenge [31]. We conclude that a half human-dose of 4CMenB is well-tolerated in mice and that a dosing regimen similar to that used in the New Zealand study elicits systemic and mucosal humoral immune responses that are cross-reactive against Ng.

Fig 1

Serum and vaginal antibody titers against F62 OMVs from 4CMenB-immunized mice.

Groups of 25 BALB/c mice were immunized three times, three weeks apart with 250 μl or 4CMenB by the IP or SC routes or with PBS or Alum (IP route). Serum and vaginal antibody titers on day 31 and day 52 (ten days after the 2nd and 3rd immunization, respectively) against F62 OMVs were measured by ELISA. Shown are serum (A) total Ig, (B) IgG1, (C) IgG2a, (D) IgA and (E) IgG1/IgG2a ratios for on days 31 and 52 (left column). Vaginal (F) total Ig, (G) IgG1, (H) IgG2a and (I) IgA on day 31 are shown in the right column. No difference was found in any sample or Ig tested between control animals receiving PBS and those receiving alum only. *, p<0.05; **, p<0.01; ***, p<0.0001. Results from the repeat experiment were similar.

4CMenB-immunized mice clear Ng infection significantly faster and have a reduced bioburden following vaginal challenge

To assess the protective efficacy of 4CMenB against Ng, we challenged 4CMenB-immunized and control mice with Ng strain F62 three weeks after the third immunization and quantitatively cultured vaginal swabs for Ng over seven days. In combined data from two independent experiments, IP-immunized mice exhibited a significantly faster clearance rate (p ≤0.0001) (Fig 2A) and lower bioburden compared to control groups given PBS or Alum alone (p <0.05 and ≤0.01, respectively) (Fig 2B and 2C). Data from each individual experiment also showed significantly faster clearance for both immunized groups compared to control mice, (S2A and S2D Fig). The bioburden in the IP-immunized group was significantly lower than that of the Alum only group in both experiments, while the difference in the bioburden in SC-immunized mice compared to Alum was significant only in the repeat experiment (p < 0.0001) (S2B and S2E Fig). Unimmunized mice from the first experiment had a significantly higher AUC compared to 4CMenB-immunized mice by either route (S2C Fig), however, in the second study only a significant reduction between the SC-immunized and alum groups was observed (S2F Fig). Combined data from the two experiments showed that 70% and 88% of mice given 4CMenB by the SC and IP routes, respectively, cleared infection by day 7 compared to 25–30% of mice given alum or PBS (Fig 2D).

Fig 2

4CMenB has in vivo efficacy against Ng.

Mice were immunized three weeks apart with 250-μL doses of 4CMenB by the IP (blue) or SC (red) route or with PBS (black) or alum (purple) by the IP route and challenged with Ng strain F62 three weeks after the final immunization. Shown are the combined data from two independent trials (total n = 38–41 mice/group). (A) Percentage of culture-positive mice over time; (B) Average CFU per ml of a single vaginal swab suspension; (C) total bioburden over 7 days expressed as area under the curve; (D) Percentage of mice that cleared infection by day 7 post-challenge. *, p < 05; **, p < 0.01; ***, p < 0.0001.

A peak vaginal PMN influx beginning on day 4 post-bacterial challenge was observed in all groups, and there was no difference in percentage of PMNs among experimental groups over time (S3 Fig). We also evaluated complement-dependent bactericidal activity of pooled serum from each group against Ng strain F62, the serum-sensitive challenge strain, and against the serum-resistant strain FA1090, using normal human serum as the complement source. The bactericidal50 titers were 1:480 and 1:240, respectively, which were 4-fold greater than that of pooled serum from the unimmunized group (Fig 3). We conclude that 4CMenB reproducibly accelerates clearance of Ng from the murine genital tract and lowers the bioburden over time and that opsonophagocytosis and complement-mediated bacteriolysis may contribute to the protection.

Fig 3

Pooled antiserum from 4CMenB-immunized mice is bactericidal against a serum-sensitive and a serum-resistant Ng strain.

Serial dilutions of pooled serum from mice vaccinated with 250 μl of 4CMenB (blue lines) or Alum alone (black lines) by the IP route were incubated with 104 CFU of the challenge strain F62 or strain FA1090 in microtiter plates as described in the Methods. After 5 min, NHS or heat-inactivated (HI)-NHS (final concentration, 10%) was added. After 55 min incubation at 37°C, the number of viable Ng in each well was determined by duplicate culture on GC agar. (A, C) Recovery of F62 (A) or FA1090 (C) from each condition expressed as the number of CFU from wells incubated with test serum divided by the number recovered from wells containing PBS instead of test serum, X times 100. Solid lines indicate NHS was used as the complement source; dotted lines represent data from wells tested in parallel with HI-NHS. The dotted line at 50% survival was drawn to identify the bactericidal50 titers. (B, D) Recovery of viable F62 (A) or FA1090 (B) from a 1:480 or 1:240 dilution of serum, respectively, from 4CMenB-immunized mice or unimmunized mice for each of three independent experiments, expressed as above. A significant difference was observed between the immunized and unimmunized serum (**, p < 0.01; ***, p < 0.0001).

4CMenB-Induced serum and vaginal antibodies cross-react with several Ng OMV proteins

To examine the cross-reactivity of 4CMenB-induced antibodies against Ng surface proteins, we performed western immunoblots against OMVs from the challenge strain and five other Ng strains that are geographically and temporally distinct in their isolation. Pooled antiserum from mice immunized twice with the 250 μL dose by either the IP or SC routes (250IP or 250SC, respectively) recognized four prominent bands in fractionated OMV preparations all six strains: a high molecular weight (HMW) band > 220 kD, a doublet with bands of apparent molecular weight of 97 and 94 kDa, and a 55 kDa band (Fig 4). Several low intensity bands between 26 and 36 kDa were also recognized in several of the strains. Reactivity of the 250SC antiserum was weaker than the 250IP antiserum, which likely reflects the lower titers of this antiserum. Consistent with ELISA data, serum reactivity as assessed by band intensity was increased by a third immunization (Fig 4A), and additional bands were recognized including several bands in the 30–35 kDa range. A similar recognition pattern was observed on blots incubated with pooled vaginal washes and sera collected 10 days after the third immunization from immunized but unchallenged mice followed by anti-mouse IgG or anti-mouse IgA (Fig 4B; compare lanes 1 and 2 with lane 5 in each blot). These results also show that while vaginal titers were low after the second immunization as measured by ELISA (Fig 1), vaccine-induced vaginal antibodies were readily detectable by immunoblot after a third immunization.

Fig 4

Serum and vaginal antibodies from 4CMenB-immunized mice recognize Ng outer membrane proteins by western immunoblot.

(A) Pooled antiserum from mice immunized with 250 μL of 4CMenB by the IP (250IP, upper panels) or SC (250SC, lower panels) route were tested against OMVs (app. 20 μg per lane) from 7 different Ng strains fractionated on 4–20% Tris-glycine gels by western blot (1:10,000 dilution of primary antisera) followed by secondary anti-mouse IgG-HRP. A boosting effect is observed when comparing the band intensities for serum collected after 2 and 3 immunizations. (B) Pooled vaginal washes from immunized or control mice collected after the third immunization tested against OMVs from the F62 challenge strain by western blot (1:100 dilution), followed by secondary anti-mouse IgG-HRP or anti-mouse IgA-HRP. Pooled vaginal washes were from mice given: (1) SC250; (2) IP250; (3) PBS; (4) Alum only. (5) 250IP mouse serum (1: 10,000) used for comparison. The band recognition pattern was similar for blots incubated with serum (lanes 5) or vaginal washes (lanes 1–4), and vaginal washes from IP-immunized mice were more strongly reactive than from SC-immunized mice. All lanes were equally loaded, as determined by Ponceau S staining. Shown are representative results from at least 2 separate experiments with identical results.

We also examined the reactivity of the immune serum against Ng lipooligosaccharide (LOS). Neisserial LOS is a branched structure that consists of oligosaccharide extensions from the core oligosaccharide called the α- and β-chains. An additional extension called the γ-chain is present in some strains [32]. Different LOS species can be produced within a strain due to phase variable expression of the glycosyltransferase genes lgtA, lgtC, lgtD and lgtG, which can reveal or mask LOS epitopes [33,34]. To test the cross-reactivity of 4CMenB antisera against Ng LOS, we fractionated crude LOS extracts by gel electrophoresis from four laboratory and thirteen clinical Ng isolates isolated between 1991 and 2019. and examined the reactivity with monoclonal antibodies (3F11, 4C4 and 2C7) that recognize known epitopes within Ng LOS [35] or with the 4CMenB antiserum by Western blot. All of the strains produced an LOS that bound one or more of monoclonal antibodies (S4A Fig). In contrast, LOS was not recognized by the 4CMenB antiserum in thirteen of the seventeen strains tested (S4B Fig). The four strains with cross-reactive LOS (MS11 and three clinical isolates LGB24, NMCSD322 and NMCSD6364) produced one or two LOS species that were recognized by the 4CMenB antiserum, but not by serum from mice given Alum adjuvant alone (S4B and S4C Fig). Schneider et al. [36] demonstrated that long-chain LOS species are selected during urethral infection in men and Rice and colleagues have shown that the phase variable 2C7 LOS epitope is expressed among a majority of clinical isolates [35]. Therefore, to test investigate whether the anti-4CMenB-reactive LOS epitope is perhaps selected in vivo, we infected mice with H041, which did not produce a cross-reactive LOS. No 4CMenB-reactive LOS species were detected in LOS preps from pooled vaginal H041 isolates cultured on days 2 and 5 post-inoculation (S4D Fig). We conclude that while cross-reactive antibodies to Ng LOS epitopes are induced by 4CMenB, the epitopes do not appear to be shared by a majority of Ng strains.

4CMenB induces antibodies against promising Ng vaccine targets

To identify the proteins recognized by 4CMenB-induced antisera, we fractionated OMVs from Ng strain F62 on two separate gels. One was stained with a G-250 Coomassie stain for mass spectrometry analysis, while the other was used for Western blotting with the 250IP antiserum. The blot and gel were aligned and the reactive bands identified by molecular weight and band intensity. Bands indicated by the numbered arrows (Fig 5A), which correspond to the most intensely recognized bands in the Western blot (Fig 5B), were submitted for mass spectrometry analysis (Table 1). The HMW band at the top of the gel was identified as PilQ, which is a protein that forms a dodecamer through which gonococcal pili extend [37]. Mass spectrometry analysis identified two proteins in band 2 (97 kDa): an elongation factor and a phosphoenolpyruvate. Band 3 (94 kDa) also contained two proteins: BamA, an Omp85 homologue involved in the biogenesis of OM proteins (OMPs) [38], and a methyltransferase. Band 4 (55 kDa) was identified as MtrE, the OM channel of the three different gonococcal active efflux pump systems [39]. The 36 kDa protein (band 5) was identified as PorB, and the 32 kDa band (band 6), as Opa. In summary, we identified eight proteins from six cross-reactive bands, five of which are known surface-exposed Ng antigens.

Fig 5

PilQ, MtrE, porin and Opa are recognized by 4CMenB antisera.

OMVs (app. 20 μg) from 6 Ng strains (Table 2) were subjected to SDS-PAGE on a 4–20% Tris-glycine gel and (A) stained with sypro ruby or (B) transferred to PVDF for western blot with the 250IP antiserum. The stained gel was aligned with the Western blot, and corresponding bands were digested and analyzed by mass spectrometry. The numbers indicated with arrows on each panel correspond to the same numbers on the Western blots except for bands 5 and 6, which were excised from a different gel but are indicated on the western based on the banding patterns. Proteins identified are described in Table 1. Among the proteins identified, known surface-exposed outer membrane proteins are: (1) PilQ, (3) BamA, (4) MtrE, (5) PorB, and (6) Opa.

Table 1

Identification of protein bands recognized by 4CMenB antisera as determined by mass spectrometry.

Sample (band)	Protein name	Database Accession IDa	MW (Da)	PeptideCountb	MS & MS/MS Scorec	Peptide sequenced ion scored	Scoring Thresholde
1	Type IV pilus biogenesis and competence protein PilQ	Q5FAD2	77903	9	556	482	55
2	Elongation factor G	B4RQX2	77124	12	852	722	55
2	Phosphoenolpyruvate synthase	KLS49216	87167	10	666	557	55
3	Outer membrane protein assembly factor BamA	Q5F5W8	87888	16	617	481	55
3	5-methyltetrahydropteroyltriglutamate—homocysteine methyltransferase	Q5F863	85030	6	227	204	55
4	Multidrug transporter MtrE	Q5F726	50382	10	452	317	55
5	Porin (PorB)	YP_208842	35516	16	969	814	55
6	PII/Opa	Q51014	31429	10	670	568	55

aFor the protein sequence, search this ID at "http://www.ncbi.nlm.nih.gov", under the parameter to "Protein";

bNumber of observed peptides matching the theoretical digest of the identified protein;

cCombined score of the quality of the peptide-mass fingerprint match and MS/MS peptide fragment ion matches (if MS/MS data was generated);

dScore of the quality of MS/MS peptide fragment ion matches only (if MS/MS data was generated);

eSignificant score threshold. A hit with an "MS & MS/MS score" or an "Ion score" above this value is considered a significant identification. p<0.05 for the given species database. Only database search hits with "MS and MSMS scores" above this value are reported.

Table 2

Bacterial strains used in this study.

Strain	Source	Location, Date	Reference(s)
N. meningitidis
MC58	blood	UK, 1983	ATCC [79]
N. gonorrhoeae (laboratory strains)
F62	urogenital	Atlanta, GA, 1962	[80]
FA1090	cervical (DGI)	Chapel Hill, NC, 1983	[81]
FA1090-ΔNhba	-	-	This report
FA6140pilQ2	pilQ mutant of FA1090		[82]
MS11	cervical	Mt. Sinai, NY, 1972	[83]
DW3-MS11	mtrE mutant of MS11		[84]
FA19	DGI	Copenhagen, 1959	[85]
N. gonorrhoeae (clinical isolates)
H041	pharyngeal	Japan, 2009	[86]
F89	urethral	France, 2011	[87]
LGB20a	urogenital	Baltimore, MD	[88]
LGB24a	urogenital	Baltimore, MD	[88]
WAMC 7720b	urethral	Fort Bragg, NC, 2014	USU GC Isolate Reference Lab and Repository [89]
WAMC 7749b	urethral	Fort Bragg, NC, 2014	As above
NMCP 4856b	urine	Portsmouth, VA, 2017	As above
NMCP 9542b	urine	Portsmouth, VA, 2017	As above
SAMMC 7363	urine	San Antonio, TX, 2016	As above
MAMC 3183	urethral	Tacoma, WA, 2015	As above
MAMC 3668	urine	Tacoma, WA, 2019	As above
NMCSD 3277	urine	San Diego, CA, 2016	As above
NMCSD 6364	urethral	San Diego, CA, 2014	As above

PorB phenotype determined by Phadebact Monoclonal GC Assay (MKL Diagnostics). All strains are PorB1b except FA19, which is PorB1a.

aLGB20 and LGB24 were collected between 1991 and 1994 and were provided by Margaret Bash, CBER/FDA.

bWAMC isolates 7720 and 7749 were isolated 6 months apart in 2014 and NMCP isolates 4856 and 9542 were isolated 3 months apart in 2017.

To examine whether 4CMenB-induced antibodies bind native PilQ and MtrE on the gonococcal surface, we next performed immunoprecipitations using 4CMenB-induced mouse antisera and live FA1090 and MS11 bacteria. Antigen-antibody complexes were solubilized in detergent, retrieved using protein A/G agarose, and subjected to non-denaturing Western blotting with the 250IP antiserum. Whole cell lysates and OMVs were run in parallel and exhibited the same reactive band pattern shown in Figs 4A and 5B. Serum from the alum-alone group pulled down non-specific proteins smaller than 30 kDa that did not align with bands in lanes containing whole cell lysates or OMVs. In contrast, the 250IP antiserum pulled down two proteins from both strains: a HMW protein, possibly PilQ, and a ~ 55 kDa protein (Fig 6). We hypothesized the 55 kD protein was MtrE based on the mass spectrometry data (Table 1) and the greater intensity of this band in western blots against OMVs from strains MS11, H041 and F89, which carry one or more mtr mutations that cause increased production of the MtrCDE efflux pump (Fig 4A).

Fig 6

4CMenB -induced antibodies bind PilQ and MtrE at the surface of viable Ng FA1090 and MS11 bacteria.

Immunoprecipitations were performed with wild-type strains FA1090 and MS11 and their isogenic pilQ and mtrE mutants using antisera from mice immunized with 250 μL of 4CMenB via the IP route (250IP) or given alum only (negative control). Bacterial components bound by 4CMenB-induced antisera were subjected to SDS-PAGE (non-denaturing conditions, 4–20% Tris-glycine) and Western blotting with 4CMenB 250IP antiserum. WCLs, total cellular proteins; OMVs, outer membrane vesicles; pilQ-, FA1090ΔpilQ; mtrE-, MS11ΔmtrE. Data shown are representative of at least 2 separate experiments with identical results. The wide band around 200 kDa corresponds to the antibodies within the test antisera that are present in the antigen-antibody complexes and pulled down with the protein A/G agarose.

To confirm the identity of the two proteins, we included single isogenic pilQ and mtrE mutants, and the results confirmed the identity of the two immunoprecipitated proteins as PilQ and MtrE. The HMW band but not the 55-kDa protein was absent from the sample in which mutant strain FA1090pilQ was incubated with the antisera. Inversely, immunoprecipitation with mutant MS11mtrE- did not yield a band around 55 kDa, but did retain binding to the HMW protein PilQ (Fig 6). We conclude that 4CMenB induces antibodies recognize the native conformation of Ng PilQ and MtrE on the gonococcal surface.

Antibodies that cross-react with PilQ and NHBA are induced in both vaccinated humans and mice

To compare the reactivity of serum from 4CMenB-immunized mice with that of humans, we performed western blots with pooled immunized mouse serum and pooled sera from study participants who had received 2 doses of the 4CMenB vaccine (Fig 7). Several Ng OMV proteins were recognized by the 4CMenB-specific human antisera (Fig 7B) compared to unimmunized serum (Fig 7C), and comparison of the blots showed recognition of at least seven bands of similar apparent molecular weight by both human and murine sera, including a prominent band at ~21 kD, bands in the 26–31 kD region, a faint band at ~37 kD, a ~46 kD band, bands in the 66–77 kD region and a ~ 83 kD band (Fig 7A and 7B). Notably, MtrE was recognized by only by antiserum from 4CMenB-immunized mice. The recognition pattern produced by individual sera from seven immunized persons was similar to that of the pooled serum, with some differences in band intensity present among the samples (Fig 8A). Most individual unimmunized serum samples recognized a ~ 62 kD and 119 kD band that were also recognized by sera from immunized subjects (but not by the immune mouse sera), and is most likely due to pre-existing antibody and not antibodies induced by vaccination (Fig 8B). A second set of immunized and unimmunized serum samples were tested against blots of gels that were fractionated for a longer period to look for recognition of PilQ, which due to its size does not always enter the gel or transfer efficiently. An intense band > 220 kD was recognized by sera from four of five immunized individuals (Fig 8C) that was not seen in sera from two unimmunized individuals (Fig 8D). The molecular weight of this band is consistent with PilQ, which was also detected by serum from immunized mice (Figs 4, 5 and 6) and confirmed by mass spectrophotometry to be PilQ (Table 1).

Fig 7

Comparison of pooled serum from 4CMenB-immunized mice and humans for cross-reactivity against Ng OMV proteins.

The reactivity of pooled serum from 4CMenB-immunized mice and humans was tested for recognition of Ng strain F62 OMV proteins by western blot. Pooled serum from unvaccinated humans was tested in parallel. Mouse antiserum was collected 10 days after the third 4CMenB immunization; human subjects were immunized with 4CMenB two times and the sera were collected between 2 and 15 months after the second immunization as described in the Methods. (A) Pooled mouse serum from 4CMenB-immunized mice, 1:10,000 dilution; (B) pooled serum from 4CMenB-immunized persons, 1:500; (C) pooled serum from unimmunized persons, 1:500. Bands of similar molecular weight that were detected by both immunized murine and human sera are indicated by the solid arrow; bands that were detected only by mouse sera are indicated by the open arrow heads. The lowest band indicated by the open arrowheads is MtrE. The faint band under the 40 kD marker indicated by the solid arrow is consistent with the apparent molecular weight of PorB. The ~ 20 kD band that is recognized by both human and mouse serum is similar in apparent molecular weight to a band that was strongly recognized by serum from a 4CMenB-immunized individual in Semchenko et al. [30]. A band of this molecular weight was also intensely recognized by IgG and IgA in vaginal washes from 4CMenB-immunized mice (Fig 4B).

Fig 8

Individual sera from 4CMenB-immunized subjects recognize several Ng OMV proteins including PilQ.

Individual sera from (A) seven 4CMenB-immunized and (B) seven unimmunized individuals were tested against Ng F62 OMV by western blot. Several bands were recognized by sera from immunized people that were not detected by sera from unimmunized subjects with the exception of bands ~ 62 kD and 119 kD, which were detected by most sera regardless of immunization status. The reactivity of individual sera from (C) five 4CMenB-immunized and (D) two unimmunized individuals was tested against Ng strain F62 OMV proteins that were fractionated by SDS/PAGE for a longer period of time to allow visualization of PilQ. An intense band above the 220 kD marker, which is consistent with the migration of PilQ, was seen in blots incubated with four of the five immunized serum samples but not when incubated with two unimmunized control serum samples. Serum from the fifth immunized individual (S11) also recognized PilQ, but much less intensely.

To identify additional proteins that appeared to be recognized by both mice and humans, we investigated whether the murine antisera recognized Neisseria Heparin Binding Adhesin (NHBA), which is one of the recombinant proteins in 4CMenB. Semchenko et al. [30] showed that sera from 4CMenB-vaccinated individuals contains antibodies that cross-react with Ng NHBA. Inspection of the western blots incubated with serum from 4CMenB-immunized mice showed a band of approximately 66 kD, which correlates with the observed molecular weight of NHBA. To determine whether this band was NHBA, we constructed an nhbp deletion mutant and performed western blots against OMVs from this mutant and its isogenic parental Ng strain, FA1090, using serum from 4CMenB-immunized mice. The results showed the absence of the most intense band in this region of the blot in the mutant OMVs relative to OMVs prepared from the parent strain (Fig 9). We conclude that the OMV portion of the 4CMenB vaccine induces cross-reactive antibodies against Ng PilQ, NHBA, and perhaps several unidentified proteins based on similarities in apparent molecular weight in both humans and mice, but that there is a species difference in the recognition of MtrE.

Fig 9

4CMenB-immunized mice have cross-reactive antibodies against Ng NHBA.

Crude OMVs (~10 μg) prepared from Ng strains FA1090 or FA1090-ΔNhba were fractionated by SDS-PAGE and transferred to nitrocellulose membranes. Western blot was performed using sera (1:2,500) from mice immunized with 4CMenB (right panel) or given alum alone (middle panel) or PBS (left panel). A band of ~ 66 kD is recognized by the immune serum in OMVs from the wild-type strain but not in OMVs from the isogenic nhba mutant FA1090-ΔNhba.

Bactericidal antibodies against one or more of these proteins may accelerate clearance of Ng in the mouse model as suggested by the presence of bactericidal activity in serum from immunized mice (Fig 3). Others have detected no or very low bactericidal activity in individuals vaccinated with 4CMenB- or NOMV-FHbp, which is an improved OMV-based serogroup B vaccine [30,40,41], while serum bactericidal activity against Ng, in contrast, was readily detected in immunized mice [40,41]. The Ng strain used in two of these studies was a highly serum-resistant strain, and therefore here we assessed the bactericidal activity of human serum from 4CMenB-immunized individuals against the serum-sensitive challenge strain used in our in vivo protection experiments. Seven of ten immunized individuals had a bactericidal50 titer ≥ 1:960 against Ng strain F62 compared to and four of eleven unvaccinated individuals, but the difference was not statistically significant (p ≤ 0.3, unpaired t test) (Fig 10). We conclude from these results that the contribution of bactericidal activity in 4CMenB-induced protection against Ng infection may differ between mice and humans; however, we did not directly investigate the role of complement in the in vivo protection we observed.

Fig 10

Serum from 4CMenB-immunized and unimmunized individuals showed no significant difference in bactericidal activity against the challenge strain.

Human serum from ten 4CMenB-immunized and eleven unimmunized individuals was tested for bactericidal activity against Ng strain F62. The bactericidal50 titer is shown for each individual (immunized: mean 1,584, median 1,200; unimmunized: mean 993, median 720). The difference in the two groups was not significant (unpaired t-test, p = 0.3). The interval between the second dose of 4CMenB and the date of serum collection ranged from 2 months (2 individuals), 4 months (6 individuals) and 15–16 months (2 individuals), with no potential correlation observed between number of months post-vaccination and bactericidal50 titer.

Discussion

The pathogenic Neisseria are human-specific pathogens that differ in the capacity to cause life-threatening septicemia and meningitis (Nm) and nonulcerative sexually transmitted infections of the urogenital tract that can ascend to cause damage to the upper reproductive tract (Ng). The only reservoir for these pathogens is human pharyngeal, genital and rectal mucosae where the bacteria reside extracellularly and within an intracellular niche [42,43]. Nm, unlike Ng, produces a complex polysaccharide capsule that is critical for invasive disease, and vaccines that target the capsules of four of the five most prevalent capsular serogroups A, C, W135 and Y have been effectively used for decades. This approach is not successful against serogroup B Nm due to the α2-8-linked polysialic acid composition of the serogroup B capsule, which mimics α2-8-sialylated human glycoproteins. A recent advance in biomedical research was the development of licensed vaccines that prevent serogroup B Nm invasive disease, one consisting of purified lipoprotein subunits, rLP2086 (Trumenba, Pfizer), and the other, 4CMenB (Bexsero, GSK) [44]. The 4CMenB vaccine was proceeded by Nm OMV vaccines that were tailor-made against endemic serogroup B strains in New Zealand, Brazil, Cuba and Norway [27,44].

Like vaccine development for serogroup B Nm, gonorrhea vaccine research has focused on conserved outer membrane proteins, Ng OMV, and in one case, the 2C7 oligosaccharide epitope within Ng LOS [18]. Vaccine development for gonorrhea is more complicated, however, due to a lack of defined immune correlates of protection. Meningococcal vaccine development is guided by serum bactericidal activity, which was identified as a correlate of protection for invasive infection in the 1960s, based on early detailed analyses of sera from case-control studies and different age groups [45]. Natural history studies for gonorrhea, in contrast, have identified only an association between antibodies against the restriction modifiable protein (Rmp) and increased susceptibility to infection, and in high-risk women, an association between antibodies to PorB and Opa proteins and reduced risk of Ng upper reproductive tract infection [18,19]. The lack of clear correlates of protection and the absence of immunity to reinfection by Ng have challenged the possibility of a gonorrhea vaccine.

It is in this context that the reported reduced risk of gonorrhea in individuals immunized with an Nm OMV vaccine [26] may herald a breakthrough for gonorrhea vaccine development. In support of this epidemiological evidence, we demonstrated that 4CMenB reproducibly accelerated Ng clearance and lowered the bioburden of Ng in a well-characterized mouse model of genital tract infection. 4CMenB induced vaginal and serum IgG1, IgG2a and IgA when administered subcutaneously that cross-react with several Ng OMV proteins expressed by six different Ng strains. These data are direct evidence of cross-species protection, and combined with our demonstration that several Ng proteins are recognized by sera from both 4CMenB-immunized mice and humans, support the use of female mice for studying vaccine-induced protection against gonorrhea.

As with many animal infection models differences in host factors including host-restricted factors must be considered when predicting whether the study outcome would occur in the natural host. Known host-restrictions that limit the capacity of mice to mimic human neisserial infections have been extensively reviewed [18] and include receptors for several neisserial colonization or invasion ligands and host scavenger proteins that are used by Ng to obtain iron [18] or zinc [46]. These restrictions limit the ability to fully evaluate the efficacy of vaccines in the mouse model that induce antibodies that block colonization or nutrient uptake although mice that are transgenic for human transferrin or carcinoembryonic antigen cellular adherence molecules (CEACAMs) could be used this purpose [47-49]. Host restrictions in two soluble negative regulators of the complement cascade, factor H (fH) and C4b-binding protein (C4BP), also exist and are especially important to consider when testing vaccines that clear Ng infection through bactericidal and opsonophagocytic activity. Transgenic hFH and hC4BP mice made for this purpose and not used in our study, were recently utilized by Rice and colleagues to more rigorously test the in vivo efficacy of immunotherapeutic strategies against Ng [50].

While unable to fully mimic human neisserial infections, animal models provide a physiologically relevant and immunologically intact system for testing vaccine-induced immune responses against infection. Meningococcal vaccine development has been aided by the use of mice and rabbits to test whether candidate vaccines cause adverse effects or induce bactericidal antibodies against Nm [51,52], and improved mouse and infant rat bacteremia models have been used to measure the efficacy of candidate Nm vaccines in eliminating Nm from the bloodstream [49,53,54]. More recently, infant rhesus macaques were employed to study immune responses to Nm OMVs, and are more predictive than mice in assessing whether these vaccines induce bactericidal antibodies against Ng in humans, perhaps due to species-specific differences in TLR-4 recognition of lipid A within these vaccines [40]. Early gonorrhea vaccine studies used chimpanzees, which do not have all the host restrictions found in other animal species, and human male subjects [18]. Chimpanzees are no longer used for gonorrhea research, however a human urethritis model is still available [55] and is the most relevant model for studying vaccine efficacy against Ng urethral infection in men.

Currently, the estradiol-treated mouse model is the only animal model for studying gonorrhea vaccine efficacy in females, where the majority of morbidity and mortality associated with gonorrhea occurs. This model is also used to systematically screen antigens, immunization regimens and adjuvants, and to analyze host responses [18]. Similarities between human and experimental murine infection include the fact that mice, like humans, produce a transient and unremarkable humoral response to Ng infection and can be reinfected with the same strain. Ng induces the Th17 pathway in both humans [19,20] and mice [56,57], which leads to recruitment of PMNs to the infection site. Similar to that reported for human cervical infections, hormonally driven, cyclical fluctuations in Ng colonization load and selection for Opa protein phase variants occurs over the course of murine infection [58]. Ng is seen within murine PMNs and importantly, Ng mutants that are more or less susceptible to killing by human PMNs or cationic antimicrobial peptides in vitro have a similar phenotype when tested against murine PMNs and cathelicidins, and are more fit or attenuated compared to the wild-type strain, respectively, during murine infection [58,59].

We also showed that the 4CMenB vaccine induced high titers of serum immunoglobulins that cross-reacted with Ng OMVs. Vaccine-induced vaginal IgA that recognized Ng proteins was readily detected by immunoblot. Recruitment of PMNs to the infection site occurred in all experimental groups, which could enable opsonophagocytic killing of Ng in the presence of specific antibody. Serum bactericidal activity was also detected that could mediate protection through complement-mediated bacteriolysis. Detailed investigation of the mechanism of protection have thus far only been reported for one candidate Ng OMV vaccine [60] and the 2C7 vaccine [35], both of which induced Th1 responses and bactericidal antibodies. The demonstration by Russell and colleagues that a vaginally applied Th1-inducing cytokine adjuvant clears Ng infection in mice and induces a specific adaptive response and protection from reinfection also suggests Th1 responses are protective [61,62]. Whether this is true for human infection is not known.

The importance of bactericidal activity in clearing Ng mucosal infections, is also not known. Passive protection studies with bactericidal monoclonal antibody against the 2C7 epitope clearly showed antibodies were sufficient for vaccine-mediated clearance in the mouse model [35]. However, this mechanism of protection may be vaccine specific. In our studies here, bactericidal activity against the serum-sensitive challenge strain was detected in pooled serum from immunized mice. A more definitive analysis, however, would be to determine whether the bactericidal activity of serum from individual mice correlates with clearance rate, which we were unable to do due to insufficient sample volumes. We did not detect a significant difference in the bactericidal50 titers of serum from immunized humans compared to unimmunized individuals against the serum-sensitive challenge strain. If 4CMenB does indeed generate protective immune responses against Ng in humans, as is widely suspected based on ecological study data, these findings suggest that it is not due to bactericidal activity. A systematic assessment of the bactericidal activity of human immune serum against a diverse panel of Ng strains may be warranted, however, due to differences in susceptibility to complement and the expression level of surface components that could cause strain-specific variation in susceptibility to 4CMenB immune sera from humans. Further investigation of the immune responses induced by 4CMenB in mice and vaccinated humans will continue to define mechanisms of vaccine-mediated protection in both species.

Recently, the proteome of the 4CMenB vaccine was defined and shown to contain 461 proteins, of which 60 proteins were predicted to be inner membrane or periplasmic and 36 were predicted to be in the outer membrane or extracellular [63]. Others identified twenty-two Nm proteins as comprising >90% of the 4CMenB proteome, twenty of which have homologs in Ng, These investigators also showed that post-vaccinated serum from 4CMenB-immunized humans recognized several bands in fractionated Ng OMVs by immunoblot [30]. In our study, the 4CMenB-induced antisera recognized several denatured OMV proteins in a panel of diverse Ng strains, which is consistent with the OMV portion of the 4CMenB vaccine generating a robust cross-reactive response. Recognition of LOS species was less impressive, with only ~25% of strains expressing LOS species that were reactive with anti-4CMenB serum. Using mass spectrometry and genetic deletion mutants, we identified several cross-reactive Ng proteins, including MtrE, PilQ, BamA, PorB, and NHBA, the gonococcal homolog of one of the recombinant components of 4CMenB. All of these proteins show promise as gonococcal vaccine targets [18,64].

The 94% amino acid identity (S1 Table) between the Nm and Ng homologs of MtrE identified in this report is consistent with the cross-reactivity that we observed. Importantly, the residues encompassing the two short surface-exposed loops of the MtrE monomer (residues 92–99 and 299–311 [65]), which are highly conserved among Ng strains, are identical to those from MtrE expressed by Nm strain MC58. MtrE is the outer membrane channel of the MtrCDE, FarABMtrE and MacABMtrE efflux pumps, which expel antibiotics and host-derived antimicrobial compounds [66]. The importance of the MtrCDE active efflux pump in protecting Ng against host innate effectors has been demonstrated in the mouse model [67]. Antisera directed against the two surface-exposed MtrE loops could target Ng for complement-mediated bacteriolysis and opsonophagocytosis, and may possibly impair efflux pump function to increase Ng susceptibility to host innate effectors. While serum from 4CMenB-immunized humans did not recognize MtrE by western blot, an MtrE subunit vaccine may induce a protective antibody response against MtrE in humans that is not generated through natural infection or when MtrE is provided to immune cells in the context of OMV, which contain many other antigens. The PilQ protein is critical for pilus secretion [68] and mutations in PilQ are associated with increased entry of heme and antimicrobial compounds [69] and enhanced resistance to cephalosporin [70]. Amino acids 406 to 770 of Nm PilQ were shown to be a promising vaccine target [71], and are 94% identical with the same region of Ng PilQ (strain FA1090). BamA is a surface-exposed outer membrane belonging to the Omp85 family [72,73]. The essential role of BamA in outer membrane protein biogenesis suggests it may be a highly effective vaccine target as it is present in cell envelopes and OMVs, surface-exposed, and well-conserved among clinical Ng isolates [38]. NHBA is an outer membrane protein that binds to heparin and other glycans and increases microcolony formation and adherence to human cervical and urethral cells [74]. Ng NHBA is well-conserved among Ng strains and 67% identical to the Nm NHBA present in the 4CMenB vaccine [64]. Although NHBA makes up a substantial portion of the immunizing antigen in 4CMenB, antibodies directed against the protein made up only a minor portion of the Ng-directed antibody responses in 4CMenB immunized mice. Immunization of mice with NHBA as a single antigen has been shown to induce bactericidal antibody responses as well as increased opsonophagocytic activity [64]. However, the relative contribution of anti-NHBA immunoglobulins induced by 4CMenB in protection against Ng still needs to be explored in mice and potentially humans.

In summary, the demonstration that a licensed Nm OMV-based vaccine accelerates Ng clearance in a murine genital tract infection model is direct evidence that cross neisserial species protection may be an effective vaccine strategy for gonorrhea. Whether this approach would protect against Ng rectal or pharyngeal infections, which are very common, is not known and in the absence of animal or human challenge models for these infections, this question must be solely addressed by epidemiological studies or clinical trials. Future detailed immunological studies in mice, which can be experimentally manipulated to directly test hypothesized mechanisms of protection, combined with clinical research studies on 4CMenB-vaccinated humans should reveal new and important information on how to combat this ancient and highly successful pathogen.

Methods

Ethics statement

All animal experiments were conducted at the Uniformed Services University according to guidelines established by the Association for the Assessment and Accreditation of Laboratory Animal Care using a protocol approved by the University’s Institutional Animal Care and Use Committee. Use of the human serum was approved by the USUHS Human Subjects Research Program Office. Serum specimens from the Department of Defense Serum Repository: The Armed Forces Health Surveillance Branch, Defense Health Agency, Silver Spring, Maryland [serum specimens 2016–2019; release dated 8/14/2019]. Human serum was collected as part of routine public health surveillance and therefore consent for this study was not available. However, samples provided for this work were deidentified (anonymous).

Bacterial strains and culture conditions

Ng strains used in this study are listed in Table 2. To delete nhba, A DNA cassette for disrupting the nhba gene in Ng strain FA1090 was generated by synthetic gene synthesis. The disruption cassette contained ~400 bp upstream and downstream of FA1090 gene NGO_1958: bp 1934786–1935186 and bp 1936476–1936874 from the complete FA1090 genome sequence, and with the Escherichia coli-derived aadA5 gene encoding spectinomycin resistance (Spcr) [75], replacing the entire coding sequence of NGO_1958. Ng strain FA1090-ΔNhba was generated by spot transformation of the disruption cassette into of strain FA1090 as described by Dillard [76] followed by selection on GC agar plates containing spectinomycin (100 mg/L). Genomic DNA was prepared from Spcr transformants, and the presence of the disrupted nhba locus was confirmed by PCR using primers spanning the coding region of nhba and within the Spcr gene (S5 Fig). The presence of the Spcr gene within the nhba locus was confirmed by nucleotide sequencing. Supplemented GC agar (Difco) was used to routinely propagate Ng as described [77]. GC-VNCTS agar [GC agar with vancomycin, colistin, nystatin, trimethoprim (VCNTS supplement; Difco) and 100 μg/ml streptomycin (Sm)] and heart infusion agar (HIA) were used to isolate Ng and facultatively anaerobic commensal flora, respectively, from murine vaginal swabs [78].

Human serum

Serum from healthy human subjects was collected as part of ongoing Department of Defense public health serosurveillance [90]. Serum was requested from deidentified subjects who were previously immunized with the recommended 2 doses of 4CMenB, and were collected as part of an ongoing U.S. Defense Health Agency (DHA), Immunizations Healthcare Division (IHD) in vitro investigation of the human immune response against Ng after 4CMenB immunization (IHBISP_18_017). Serum specimens were collected between 2–16 months after the last 4CMenB immunization for the immunized samples. Sera from non-immunized controls were also available from the IHB-funded study.

Immunizations and challenge experiments

Four-week-old female BALB/c mice (Charles River; NCI Frederick strain of inbred BALB/cAnNCr mice, strain code 555) were used in these studies. In pilot immunization studies, groups of 5 mice each were immunized with 20, 100 or 250 μL of 4CMenB (GSK) by the intraperitoneal (IP) or subcutaneous (SQ) routes on days 0 and 28. Two independent immunization and challenge experiments were conducted. For these experiments, 250 μL of the vaccine were given IP or SC on days 0, 21 and 42. Control mice received PBS or alum in the form of Alhydrogel (InVivogen) diluted in PBS (n = 20–25 mice/group). Venous blood was collected on days 31 and 52; vaginal washes were collected on day 31. Three weeks after the final immunization, mice in the anestrus or the diestrus stage of the reproductive cycle were implanted subcutaneously with a 21-day slow-release 17β-estradiol pellet (Innovative Research of America) and treated with antibiotics to suppress overgrowth of potentially inhibitory flora as described [58]. Two days after pellet implantation, mice were inoculated vaginally with 106 colony-forming units (CFU) of Ng strain F62. Vaginal swabs were quantitatively cultured for Ng on 7 consecutive days post-challenge and used to prepare stained smears to examine the influx of vaginal polymorphonuclear leukocytes (PMNs) [78].

Enzyme-linked immunosorbent assay (ELISA) and western blots

Serum or vaginal total Ig, IgG1, IgG2a and IgA were measured as endpoint titers as determined by standard ELISA [91]. Microtiter plates were coated with 20 μL/well of a 1:5 dilution of the formulated Bexsero vaccine in 15 mM Na2CO3, 35 mM NaHCO3, pH 9.5, or with 4 μg/ml of OMV from Ng strain F62. OMVs were isolated from supernatants from late-logarithmic phase cultures that were centrifuged for 1 hour at 100,000 x g at 4°C. Pellets were resuspended in 1 mL of PBS. Protein concentration was determined by the BCA protein assay (Thermo Scientific). For whole-cell lysates (WCL) (total cellular proteins), bacteria from agar plates or mid-logarithmic phase cultures were centrifuged and the bacterial pellets suspended to an OD600 = 0.5. One milliliter of this suspension was mixed with 60 μL of Laemmli sample buffer. For western blots, WCL (4 μL) or 20 μg of OMV were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membranes, stained with Ponceau S, and blocked overnight with 0.5% Tween20 in PBS. Membranes were incubated with pooled antisera or vaginal washes from each experimental group diluted in block and washed three times with 0.05% Tween 20 in PBS. Secondary antibody was horseradish peroxidase (HRP)-conjugated anti-mouse IgG or IgA and a chemiluminescence HRP was used as substrate (GE Healthcare). For western blots with human serum, immunized and unimmunized sera were diluted 1:500; secondary antibody was horseradish peroxidase (HRP)-conjugated anti-human IgG. Apparent molecular weight of bands was determined using a standard curve generated from molecular weight markers (r2 = 0.9916). For western blots with LOS, proteinase K-treated bacterial extracts were generated as described [92] without the phenol treatment step, separated on 16% tricine gels (Novex) and probed with 1:10,000 dilutions of pooled serum from immunized and control mice followed by HRP-conjugated anti-mouse IgG as above.

Immunoprecipitation and mass spectrometry

Two milliliters of a Ng suspension (OD600 = 1) prepared from a mid-logarithmic phase Gc broth culture were mixed with 30 μL of antisera for 20 minute at room temperature. Cell pellets were washed once with GCB and solubilized in 2% Zwittergent 3,14 (EMD Millipore) in PBS for one hour at 37°C. The solubilized suspension was centrifuged for 10 minutes at 2,000 x g, the supernatant mixed with protein A/G resin (ExAlpha Biologicals) for two hours at 4°C with mixing, and the resin washed three times with 0.5% Zwittergent 3,14 in PBS, and once with PBS alone. The resin was suspended in 50 μL Laemmli sample buffer without β-mercaptoethanol and subjected to SDS-PAGE for Western blotting; a duplicate gel was run in parallel and stained with Coomassie G-250. Bands from the stained gel were submitted to the Michael Hooker Proteomics Center at the University of North Carolina at Chapel Hill for trypsin digest and identification using mass spectrometry. Accession ID numbers of proteins described in this report are disclosed in Table Table 1 and S1 Table. Alignment of amino acid sequences was performed using ClustalW.

Bactericidal assay

A modification of a previously described bactericidal assay [93] was used to test the bactericidal activity of mouse and human serum. Pooled sera from immunized and control mice were heated at 56°C for 30 min and serially diluted 1:2 in minimal essential medium (MEM) (1:30–1:960). Fifty microliters of each dilution were pipetted into wells of a 96-well microtiter plate. Fifty microliters of an MEM suspension containing 100–400 CFU of the target strain were added to the wells and to a well containing 50 μl of MEM alone. After 5 minutes incubation at RT, 50 μl of pooled normal human serum (NHS) (PelFreeze) were added to each well (final concentration 10%) and the plate was incubated for 55 minutes at 37°C in 5% CO2. Fifty microliters of GC broth were then added, mixed, and 50 μl aliquots were cultured in duplicate on GC agar and incubated overnight. The antiserum dilution that gave 50% recovery compared to wells without antiserum was defined as the bactericidal50 titer. Wells containing heat-inactivated NHS were tested in parallel to measure complement-independent loss of bacterial viability during the assay; no appreciable loss was detected in any experiment. Human sera were tested using the same assay, with pooled sera from five 4CMenB-immunized subjects and five unimmunized subjects tested initially, followed by bactericidal assays with individual sera from ten immunized and eleven unimmunized subjects. The assays were performed against each strain in two independent experiments; a third assay was performed for those titers that differed in the first two experiments, and the titer that was identified in two of the three iterations was used.

Statistical analysis

ELISA titers were compared by a Kruskal-Wallis test with Dunn’s multiple comparison. For challenge experiments, the percentage of mice with positive cultures at each time point was plotted for each experimental group as a Kaplan Meier curve and analyzed by the Log Rank test. The number of CFU recovered from vaginal swabs over time was compared by repeated measures ANOVA with Bonferroni correction. The area under the curve (AUC) was calculated for each individual mouse by determining the AUC across the 7 culture time points that was above the limit of detection (20 CFU/mL). Differences between AUC and percentage of vaginal PMNs were compared using a Kruskal-Wallis test with Dunn’s multiple comparison. Differences in bactericidal50 titers were assessed by unpaired t and Mann Whitney tests. Statistical analyses were performed using the software Prism (GraphPad Software, La Jolla, CA). Raw data used for statistical analysis of ELISA, in vivo efficacy testing, and mouse bactericidal assays have been published [94].

Amino acid identity between proteins of N. meningitidis MC58 and N.

(DOCX)

Click here for additional data file.

Pilot dose response immunization study with the 4CMenB vaccine.

Groups of 5 BALB/c mice were given 20, 100 or 250 μl of the formulated vaccine on days 1 and 28 by the IP or SC routes. (A,B) Serum IgG1 and IgG2a titers using microtiter plates coated with the formulated 4CMenB vaccine 10 days after the second immunization. A dose response is shown for serum IgG1 in both IP- and SC-immunized mice. (C) Serum reactivity (1:5,000) against whole cell lysates of Nm strain MC58 and of 6 different Ng strains using anti-mouse IgG secondary antibody shows a similar dose response based on differences band intensity. A nonparametric test (Kruskal Wallis with Dunn’s multiple comparison) was used to analyze ELISA data due to the low sample size. **, p < 0.01.

(TIF)

Click here for additional data file.

4CMenB significantly accelerated Ng clearance and reduced the Ng colonization load in two independent experiments.

In each experiment, mice were immunized three weeks apart with 250-μl doses of 4CMenB by the IP (blue) or SC (red) route or given PBS (black) or alum (purple) by the IP route (n = 25 or 20 mice per group in experiments 1 (A-C) and 2 (D-F), respectively). Three weeks after the final immunization, mice were challenged with Ng strain F62 as described in the Methods. (A,D) Percentage of culture-positive mice over time and average CFU per ml of a single vaginal swab suspension, respectively for experiment 1 (n = 20–23 mice/group); (B,E) Percentage of culture-positive mice over time and average CFU per ml of a single vaginal swab suspension, respectively for experiment 2 (n = 18–19 mice/group); (C,F) Total bioburden recovered from individual mice over 7 days expressed as area under the curve (AUC) for experiments 1 and 2, respectively. The median with 95% CI is indicated for each group.*, p < 0.05, **p < 0.01, *** p < 0.0001.

(TIF)

Click here for additional data file.

A vaginal PMN influx occurred in all experimental groups.

Vaginal smears collected on each culture day following bacterial challenge were stained with Hemacolor Stain (Sigma), and the percent of PMNs among 100 vaginal cells was determined by cytological differentiation using light microscopy. An increase in the percentage of PMNs occurred between days 4–7 as is characteristic of this model, with no statistical difference between the groups. The median percent PMNs is shown by the horizontal bar for each time-point.

(TIF)

Click here for additional data file.

4CMenB antiserum recognizes Ng LOS in a minority of strains.

Proteinase K-treated bacterial extracts from 4 laboratory strains and 13 clinical isolates were resolved on 16% Tricine gels and stained with silver stain (top blot, panel A) or Emerald green (top blots, panels B and D), or electroblotted and probed with the following: (A) Mabs 3F11, 4C4 and 2C7, which recognize Ng LOS epitopes (bottom panels). Note that FA19 1986 is a variant of FA19 (panel B) that has a phase-off lgtA gene that results in truncation of the LOS to a single 3.6 kDa species [95]. (B) Pooled IP250 4CMenB antisera (bottom panels). The doublets in LGB-24 and NMCSD 3277 and single LOS species in MS11 and NMCSD 6364 that were recognized by the antiserum are distinct from the LOS species identified by the Mabs shown in Panel A. (C) Western blots against LOS from strains with 4CMenB-reactive bands incubated with pooled sera from 4CMenB-immunized mice versus mice given Alum only. (D) Emerald green-stained (upper panel) LOS from Ng strain H041 and LGB-24 (positive control) used to inoculate mice (Inoc) and from vaginal cultures collected on days 2 and 5 of infection. No change in the LOS species or 4CMenB reactivity was observed during infection by these strains.

(TIF)

Click here for additional data file.

Disruption of nhba in Ng strain FA1090.

(A) Schematic of the synthetic Ng nhba disruption cassette showing 400 bp homology arms 5’ and 3’ from the nhba Ngo_1958) coding sequence, which is completely removed and replaced with a Spcr gene. The approximate location of primers used for polymerase chain reaction to detect the disrupted gene and he predicted size of the amplification products is noted. (B) Disruption cassette (Lane 1), and genomic DNA from FA1090 (Lane 2) and FA1090-Δnhba (Lane 3) were used as template for PCR with the indicated primers. The products of the amplification reactions were run on 1X TBE agarose gels and visualized with ethidium bromide staining. Oligonucleotide sequence primers were: Primer 1: ACGTTTTGTTTACCGCTGCC; Primer 2: TTCGGGGGCTTGTTTGATGA; Primer 3: CGTTGTCCCGCATTTGTAC.

(TIF)

Click here for additional data file.

7 Jun 2020

Dear Ann,

Thank you very much for submitting your manuscript "The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Reviewer 2 raises important issues relating to how the results described here relate to immune responses detected in humans following immunisation with Bexsero (reported by Semchenko et al.,). Further comments about the differences and similarities are warranted.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

best,

Chris

Christoph Tang

Section Editor

PLOS Pathogens

Christoph Tang

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer 2 raises important issues relating to how the results described here relate to immune responses detected in humans following immunisation with Bexsero (reported by Semchenko et al.,). Further comments about the differences and similarities are warranted.

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: Leduc et al show that immunizing mice with MenB-4C (Bexsero) results in attenuation of gonococcal vaginal colonization. Pooled post-dose 3 immune serum showed bactericidal activity against strains F62 and FA1090. Ng proteins (eg, MtrE, BamA and PilQ) recognized by IgG from immune mouse serum have been identified. This is an important study in light of the 31% clinical efficacy of the MeNZB vaccine against gonorrhea in New Zealand. How MeNZB (and possibly the related vaccine, Bexsero) may act to provide some immunity against gonorrhea remains unclear. This paper uses a mouse model of gonorrhea to address this issue. The presentation of some of the results needs further clarification. The discussion also needs to be modified to take into consideration related work in the field and tie together observations and also highlight the differences between this study and recent studies of Bexsero immunogenicity versus N. gonorrhoeae in humans and macaques.

Reviewer #2: This manuscript describes the results of vaccine studies using Bexsero in an estradiol treated mouse model of vaginal gonorrhea. The manuscript is well written and presents the data in a detailed fashion. It is clear that considerable effort and thought has gone into the design of the experiments. The most important question which needs to be addressed is how closely this model simulates human disease and can be murine response be utilized to allow selection of antigens for a successful human gonococcal vaccine. This reviewer believes that the authors of this manuscript have failed to justify the results the obtained in this regard.

Reviewer #3: It is seldom that I have a chance to review a paper that is a real pleasure to read. This manuscript describes an extremely important, in some ways game-changing, study related to the development of vaccines against Ng (N. gonorrhoeae), a goal that has been elusive despite decades of study. The genesis of this paper is the observation of efficacy against Ng infection in a field trial of a vaccine against Nm (N. meningitides). These authors have taken that observation into the laboratory by demonstrating similar protection in a murine mouse model of N. gonorrhoeae infection developed by the senior author some time ago. This one-two punch is a major cause for optimism in the quest for a vaccine, one because, feasibility of a vaccine approach in a clinical trial has been demonstrated, and two because this model provides the opportunity to dissect mechanisms of protection, and to evaluate new vaccine candidates prior to human trials. The paper is very well written, and the experiments proceed logically. In fact, as I read, I found that experiments I was wanting to see, were in fact included already. To restate the significant findings of this paper: 1) A human Nm vaccine found to provide some efficacy against Ng in a clinical trial, was found to do the same in a mouse model of Ng infection. 2) Outer membrane protein candidate antigens identified by mouse immune sera illuminate paths forward for Ng vaccine development. 3) antibodies against LOS do not appear to be involved in mediating protection. 4) The mouse model has been validated as a tool for study of immunity to Ng infection. An additional aspect of this paper was the quality of the introduction and the discussion. Both nicely put this work in historical perspective in a concise and clear manner.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: (No Response)

Reviewer #2: A.The mice in the current study showed significant bacteridical activity against both serum sensitive and serum resistant gonococcal strains (Figure 3). In the Semchenko study, humans immunized with Bexsero did not develop a bactericidal response to the gonococcus. While it can be difficult to compare, the intensity of the immune response both in the number of antigens and types recognized in the murine response was considerably greater both by western blot and ELISA measurements than the human Bexsero response. The gonococcal literature since the mid-1970s has been replete with studies that have shown murine immune responses to pilus, porin and LOS epitopes which the human immune system either cannot or does not recognize. It would appear comparing the results of the Semchenko paper to this manuscript that we may be seeing the same situation in this model.

B. For the results obtained in this model to be accepted as valid surrogates of the human response, it would be necessary to take the results from the murine system and demonstrated they have meaning in a human system. One possible way to do this would be to demonstrate that an anti-mtrE response is a significant part of the human response to Bexsero. Semchenko demonstrated a robust Neisseria Heparin binding antigen response in Bexsero immunized human sera by ELISA. The authors should consider taking at least one of the three antigens which appear to be potential vaccine candidates in the mouse model and show that antibodies to it, are present in Bexsero immunized human sera. Wang and Associates (J. Infection, 2018, 71:191-224) showed that mice immunized with mtrE surface exposed peptides showed protection in the same murine model of gonococcal infection. Using these peptides, the authors could address this issue directly if they want to prove that their model useful in identifying potential human vaccine candidates.

Reviewer #3: As stated in the summary above, I feel that all of the major points and conclusions of this paper are well supported by the experimental evidence. I did not identify any necessary additional experiments.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: 1. The graphs in Fig 3 should show the killing over the entire range of concentrations – 1:30 to 1:960 (note the graph shows a range of 120 to 1920, while methods mention dilutions from 1:30 to 1:960, so need to unify). Please also show each value at least for the samples that got NHS – the methods state 2-3 independent experiments. Were the differences statistically significant? Also, what do the data points represent – mean, median?

2. The reason for pooling sera for bactericidal assays should be stated. This limitation will overlook heterogeneity in bactericidal responses across animals and should be discussed.

3. The authors have made a considerable effort to look for antibody responses to LOS (Fig 5). The OMVs in Bexsero are detergent-extracted, therefore contain only trace amounts of LOS. The anti-LOS cidal Ab described in Ref 32 were elicited after immunization with LPS-containing vaccine (NOMVs or detoxified LPS conjugated to proteins). The anti-LPS cidal Ab seen in children who got the Chilean vaccine (detergent-extracted OMV, contains <1% LPS) were seen 6 or more months after the last dose of vaccine, suggesting that they developed as a result of subsequent meningococcal colonization. Thus, rationale provided for looking at LOS response (lines 217-8) is unclear. It is not surprising that there is a limited response to LOS (from the presented data its not discernable whether pre-immune or adjuvant sera also would have reacted with Ng LOS). Note that humans immunized with Bexsero barely mount an Ab response to meningococcal or Ng LOS over baseline (see Supp Fig 6 in Semchenko et al, Clin Infect Dis, Vol 69, Issue 7, p 1101–1111). I suggest this entire section on LOS be removed or stated as a single sentence. The corresponding sentence in the abstract (lines 46-7) should also be deleted and Table 2 modified accordingly.

4. The discussion focuses excessively on justification of use of this mouse model, and the possible advantages of transgenic mice. These portions (lines 332-372) can be considerably shortened and some of the comprehensive, outstanding reviews by the authors cited instead. The discussion should instead focus on how these results relate to other similar work (please see below).

5. There should be a discussion of how these results compare to results reported by Semchenko et al, who examined Ng cross-reactive antibodies in humans given Bexsero. Were similar Ng proteins identified by immune mouse and human sera? Agreeably, the cross-reactive proteins, with the exception of NHBA, were not fully characterized in that study but it would be worth commenting on differences in molecular weights of the target proteins. It appears that the major Ng protein recognized in Bexsero immunized humans is in the ~25 kD range and against NHBA but does not appear to be the case here. These mouse/human differences are important and merit discussion.

6. Minimal bactericidal activity versus FA1090 was observed with serum from macaques immunized with Bexsero when tested at a 1:5 dilution (Beernink et al, mBio. 2019 Jun 18;10(3):e01231-19.). Humans given MenB-4C also do not show bactericidal activity against FA1090 (Beernink et al. J Infect Dis. 2019 Apr 1; 219(7): 1130–1137). Possible reasons for differences in the serum bactericidal responses across the species should be discussed.

7. Lines 386-389 “…; however, eleven other promising…. (..unpublished data…)”. This part of the sentence should either be substantiated with data or deleted. This reviewer acknowledges that vaccines may function through mechanisms other than complement-dependent killing. Reports of high cidal titers need to be interpreted cautiously. This is because mice and rabbits often develop natural bactericidal Abs vs Ng with age and bactericidal assays reported for gonococcal vaccine candidates sometimes lack critical age-matched adjuvant controls, and thus does not account for the effect of these natural cidal Ab (eg, PMID: 27141096; PMID: 27895130). This study demonstrates baseline bactericidal activity in the pooled serum from unimmunized age-matched mice – a key control.

8. Line 71 – 87 million new infections (Rowley et al, Bull World Health Organ 2019;97:548–562P)

9. Line 127 – NHBA (not NHBP)

10. Was the NHS from Pel-Freez IgG and IgM depleted?

11. What dilution of serum was used in S1 Fig, panel C?

12. Please also show the Area Under Curves for each individual mouse experiment (S2 Fig).

13. Minor details/discrepancies in cidal methods in methods vs Fig legends – methods state 100-400 CFU used, legend states 10^4 bacteria. Time of incubation – 55 min in methods, 45 min in Fig legend.

14. Line 316 –The meningococcal group C outbreak described in Ref 44 occurred at Fort Dix, NJ (not Fort Ord, CA).

15. Lines 328-329 – only the 3 doses were similar, not the regimen. The vaccine preparation and the dosing interval were both different. Suggest deleting this sentence.

Reviewer #2: (No Response)

Reviewer #3: I have no additional editorial suggestions.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Michael A. Apicella, M.D.

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at .

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see

6 Oct 2020

Submitted filename: Response to the Reviewers - Leduc et al., Oct 6, 2020.docx

Click here for additional data file.

8 Oct 2020

Dear Dr Jerse,

We are pleased to inform you that your manuscript 'The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Christoph Tang

Section Editor

PLOS Pathogens

Christoph Tang

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

28 Nov 2020

Dear Dr Jerse,

We are delighted to inform you that your manuscript, "The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064